Clinical Chemistry Siemens Point of Care - Urinalysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 1820-1826, 2007. First published August 23, 2007; 10.1373/clinchem.2007.091629
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow 091629.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2007.091629v1
53/10/1820    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Worsley, G. J.
Right arrow Articles by Pritchard, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Worsley, G. J.
Right arrow Articles by Pritchard, J.
Related Collections
Right arrow Endocrinology and Metabolism
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2007;53:1820-1826.)
© 2007 American Association for Clinical Chemistry, Inc.

Automation and Analytical Techniques

Continuous Blood Glucose Monitoring with a Thin-Film Optical Sensor

Graham J. Worsley, Guilhem A. Tourniaire, Kathryn E. S. Medlock, Felicity K. Sartain, Hazel E. Harmer, Michael Thatcher, Adrian M. Horgan and John Pritcharda

Smart Holograms Ltd., Cambridge, United Kingdom.

aAddress correspondence to this author at: Smart Holograms Ltd., 291 Cambridge Science Park, Milton Rd., Cambridge CB4 0WF, United Kingdom. Fax 44 (0) 1223 393401; e-mail john.pritchard{at}smartholograms.com.

Background: We recently described a holographic optical sensor with improved selectivity for glucose over fructose that was based on a thin-film polymer hydrogel containing phenylboronic acid receptors. The aim of the present work was to measure glucose in human blood plasma as opposed to simple buffers and track changes in concentration at a rate mimicking glucose changes in vivo.

Methods: We used holographic sensors containing acrylamide, N,N'-methylenebisacrylamide, 3-acrylamidophenylboronic acid, and (3-acrylamidopropyl)trimethylammonium chloride to measure 7 human blood plasma samples at different glucose concentrations (3–33 mmol/L) in static mode. Separately, using a flow cell, the glucose concentration was varied at approximately 0.17–0.28 mmol–1 · L–1 · min–1, and the sensor’s ability to continuously monitor glucose was investigated over an extended period.

Results: We subjected the results of the ex vivo static measurements to error grid analysis. Of 46 measurements, 42 (91.3%) fell in zone A of a Clarke error grid, and the remainder (8.7%) fell in zone B. The ex vivo flow experiments showed that the sensor is able to accurately track changes in concentration occurring in real time without lag or evidence of hysteresis.

Conclusions: We demonstrate the ability of a phenylboronic acid–based sensor to measure glucose in human blood plasma for the 1st time in vitro. Holographic glucose sensors can be used without recourse to recalibration. Their robust nature, coupled with their format flexibility, makes them an attractive alternative to conventional electrochemical enzyme-based methods of glucose monitoring for people with diabetes.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.